Literature DB >> 11694453

Interleukin-13 induces dramatically different transcriptional programs in three human airway cell types.

J H Lee1, N Kaminski, G Dolganov, G Grunig, L Koth, C Solomon, D J Erle, D Sheppard.   

Abstract

Interleukin (IL)-13, a cytokine released by T lymphocytes during immediate hypersensitivity responses, is a central mediator of asthma. Because IL-13 induces phenotypic features of asthma in mice deficient in T and B lymphocytes, it is likely that this cytokine contributes to the development of asthma by acting directly on resident airway cells. To analyze the global effects of IL-13 on gene expression in airway cells that could contribute to the phenotypic features of asthma, we used Genechip HuGene FL arrays (Affymetrix, Santa Clara, CA) that contain probes for approximately 6,500 human genes. Despite activating a common signaling pathway, IL-13 induced dramatically different patterns of gene expression in primary cultures of airway epithelial cells, airway smooth muscle cells, and lung fibroblasts, with little overlap among cell types. The most prominent effects of IL-13 were on airway smooth muscle, but several genes induced in airway epithelial cells and fibroblasts are also candidates that may contribute to phenotypic features of asthma. These results suggest that the in vivo response to IL-13 in the airways likely results from a combination of distinct effects on each of several resident airway cell types.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11694453     DOI: 10.1165/ajrcmb.25.4.4522

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  53 in total

Review 1.  JAK-STAT signaling in asthma.

Authors:  Alessandra B Pernis; Paul B Rothman
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  IL-13 and adenosine: partners in a molecular dance?

Authors:  Gabriele Grünig
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

3.  Functional expression of IgG-Fc receptors in human airway smooth muscle cells.

Authors:  YuXiu C Xia; Michael Schuliga; Malcolm Shepherd; Maree Powell; Trudi Harris; Shenna Y Langenbach; Peck Szee Tan; William T Gerthoffer; P Mark Hogarth; Alastair G Stewart; Graham A Mackay
Journal:  Am J Respir Cell Mol Biol       Date:  2010-07-01       Impact factor: 6.914

Review 4.  Mechanisms of fibrosis: therapeutic translation for fibrotic disease.

Authors:  Thomas A Wynn; Thirumalai R Ramalingam
Journal:  Nat Med       Date:  2012-07-06       Impact factor: 53.440

Review 5.  Gene expression profiling in human asthma.

Authors:  Nadia N Hansel; Gregory B Diette
Journal:  Proc Am Thorac Soc       Date:  2007-01

6.  Cytokine-mediated control of lipopolysaccharide-induced activation of small intestinal epithelial cells.

Authors:  Michael Lotz; Till König; Sandrine Ménard; Dominique Gütle; Christian Bogdan; Mathias W Hornef
Journal:  Immunology       Date:  2007-05-18       Impact factor: 7.397

Review 7.  Host responses in tissue repair and fibrosis.

Authors:  Jeremy S Duffield; Mark Lupher; Victor J Thannickal; Thomas A Wynn
Journal:  Annu Rev Pathol       Date:  2012-10-22       Impact factor: 23.472

8.  IL-13 enhances agonist-evoked calcium signals and contractile responses in airway smooth muscle.

Authors:  Omar Tliba; Deepak Deshpande; Hang Chen; Christopher Van Besien; Mathur Kannan; Reynold A Panettieri; Yassine Amrani
Journal:  Br J Pharmacol       Date:  2003-11-03       Impact factor: 8.739

9.  Interleukin-13-induced mucous metaplasia increases susceptibility of human airway epithelium to rhinovirus infection.

Authors:  Marrah E Lachowicz-Scroggins; Homer A Boushey; Walter E Finkbeiner; Jonathan H Widdicombe
Journal:  Am J Respir Cell Mol Biol       Date:  2010-01-15       Impact factor: 6.914

Review 10.  New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.

Authors:  Neil Ahluwalia; Barry S Shea; Andrew M Tager
Journal:  Am J Respir Crit Care Med       Date:  2014-10-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.